April 12, 2016
Yesterday the National Academies of Sciences, Engineering and Medicine released Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report, which affirms that it would be possible to eliminate hepatitis in the U.S. with the right resources, commitment, and strategy. Importantly, the report also concluded that in the short term, disease control -- a reduction in the incidence and prevalence of hepatitis B and C and their consequences -- is feasible.
Commissioned by the CDC's Division of Viral Hepatitis and the HHS Office of Minority Health, the report examines scientific and policy issues related to the prevention, detection, control, and management of HBV and HCV and also discusses the barriers that must be overcome to eliminate hepatitis B and hepatitis C in the United States.
This report will inform and galvanize work currently underway across the federal government to both implement the national Viral Hepatitis Action Plan and develop an update to it that will guide our nation's response to viral hepatitis through 2020. (See the related blog post: Federal Workgroup Looks to Future of Viral Hepatitis Action Plan.)
The Academies will now continue their work, developing a phase two report that will outline a strategy and propose targets for eliminating hepatitis B and C in the United States. This report is expected early next year.
Corinna Dan, R.N., M.P.H., is a viral hepatitis policy advisor at the Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|